August 31, 2020
Mylan and Biocon Biologics have launched Semglee™ (insulin glargine injection) in vial and pre-filled pen dosage forms. The product is FDA-approved to help control blood sugar in adult and pediatric patients who have type 1 diabetes and adults diagnosed with type 2 diabetes.
Semglee has the same amino acid sequence as its reference product, Lantus® (insulin glargine injection – Sanofi), and is approved for the same indications. However, it is not automatically interchangeable. Mylan and Biocon are currently seeking to have Semglee designated as a Lantus biosimilar by the FDA.
Mylan and Biocon have priced Semglee at a 65% discount to Lantus, with a wholesale acquisition cost (WAC) of $147.98 per package of five 3mL pens and $98.65 per 10mL vial. This is the lowest WAC for any long-acting insulin glargine currently on the U.S. market.